In our January post on what we planned to watch for in 2018, we predicted that digital health would come to the foreground of activity this year. And indeed, we are starting to see a lot of buzz around digital health. In March, Novartis and Pear Therapeutics announced the first development deal between a major...
Adherence to prescription drug therapies is a big problem, not only for patients and drug developers, but also for payers who cover the costs of such medications and then pay to treat problems the drugs were meant to prevent. About 10 years ago, the New England Journal of Medicine estimated that up to two-thirds of...